Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
暂无分享,去创建一个
Sui Shen | Christine Hartmann-Siantar | Aina Yuan | G. Denardo | S. Denardo | S. Shen | Gerald L DeNardo | Sally J DeNardo | Robert T O'Donnell | A. Yuan | C. Hartmann-Siantar | R. O'donnell
[1] G. Denardo,et al. Practical determination of organ S values for individual patients for therapy. , 1997, Nuclear medicine and biology.
[2] C S Chui,et al. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. , 1997, Medical physics.
[3] R. Ceriani,et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] G. Denardo,et al. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] R Mohan,et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] J. McGahan,et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. , 1998, Cancer biotherapy & radiopharmaceuticals.
[7] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Lamborn,et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. , 1997, Anticancer research.
[9] G. Denardo,et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. , 1998, Anticancer research.
[10] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[11] G. Denardo,et al. Impact of splenomegaly on therapeutic response and I‐131‐LYM‐1 dosimetry in patients with B‐lymphocytic malignancies , 1997, Cancer.
[12] M G Stabin,et al. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] G. Denardo,et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] D A Podoloff,et al. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] L. Gordon,et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. W. Beck,et al. Volume determinations using computed tomography. , 1982, AJR. American journal of roentgenology.
[17] G. Denardo,et al. Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients , 1988 .
[18] J. McGahan,et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S Shen,et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] T. Economopoulos,et al. Splenectomy in patients with malignant non‐Hodgkin's lymphoma , 2000, European journal of haematology.
[21] L. M. Cobb,et al. Internal dosimetry using data derived from autoradiographs. , 1993, Journal of Nuclear Medicine.
[22] G. Denardo,et al. Determination of spleen size by scintigraphy. , 1999, Cancer biotherapy & radiopharmaceuticals.
[23] K. Lamborn,et al. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] J. L. Coffey,et al. Calculating dose from remaining body activity: a comparison of two methods. , 1979, Medical physics.
[25] M. Stevens,et al. The effect of abdominal radiation on spleen function: a study in children with Wilms' tumor. , 1986, Pediatric hematology and oncology.